In a filing, EyePoint Pharmaceuticals Inc revealed its Director ANTHONY P. ADAMIS acquired Company’s shares for reported $0.67 million on Oct 23 ’24. In the deal valued at $10.04 per share,67,100 shares were bought.
Then, David R. Guyer bought 36,975 shares, generating $329,817 in total proceeds.
Before that, DICICCO WENDY F bought 2,567 shares. EyePoint Pharmaceuticals Inc shares valued at $19,997 were divested by the Director at a price of $7.79 per share. As a result of the transaction, DICICCO WENDY F now holds 9,967 shares, worth roughly $86513.56.
Scotiabank initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. JP Morgan began covering EYPT with “an Overweight” recommendation on January 22, 2024. Mizuho started covering the stock on November 02, 2023. It rated EYPT as “a Buy”.
Price Performance Review of EYPT
On Monday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock jump 5.08% to $8.68. Over the last five days, the stock has gained 20.56%. EyePoint Pharmaceuticals Inc shares have risen nearly 16.51% since the year began. Nevertheless, the stocks have fallen -56.45% over the past one year. While a 52-week high of $30.99 was reached on 01/06/25, a 52-week low of $6.90 was recorded on 01/02/25. SMA at 50 days reached $9.20, while 200 days put it at $10.96.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 8.30, which if violated will result in even more drops to 7.92. On the upside, there is a resistance level at 9.13. A further resistance level may holdings at 9.58. The Relative Strength Index (RSI) on the 14-day chart is 56.37, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.75, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 22.61%. Stochastics %K at 80.40% indicates the stock is a selling.
How much short interest is there in EyePoint Pharmaceuticals Inc?
A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc stocks on 2024-12-13, dropping by -0.46 million shares to a total of 9.41 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 9.88 million shares. There was a decline of -4.93%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 21, 2023 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $33 price target.
